CYP2D6 and the pharmacokinetics of ibogaine
Phase 1
Completed
- Conditions
- Opioid dependenceMental Health - Studies of normal psychology, cognitive function and behaviour
- Registration Number
- ACTRN12613000324718
- Lead Sponsor
- niversity of Otago
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 24
Inclusion Criteria
Healthy volunteers, drug free, good general health, normal screening lab tests and ECG
Exclusion Criteria
Significant medical history, drug use
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Plasma pharmacokinetics of ibogaine and its active metabolite[predose, 0.5, 1.0, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144 and 168h]
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What is the role of CYP2D6 in ibogaine metabolism and opioid dependence treatment?
How does ibogaine pharmacokinetics vary with CYP2D6 genotypes in healthy volunteers?
Are there biomarkers that predict ibogaine response in CYP2D6 poor metabolizers for opioid addiction?
What adverse events are associated with ibogaine administration in CYP2D6-related studies and how are they managed?
How does ibogaine compare to standard-of-care treatments for opioid dependence in phase I trials?